Developing Innovative Treatments for Stroke and Other Vascular Diseases

Learn more about Diamedica

About Diamedica

DiaMedica is a publicly traded (TSX-V:DMA) development stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat vascular and metabolic diseases.

About Diamedica
Learn more about Diamedica

Product Pipeline

DiaMedica’s lead clinical stage product, DM199, is a recombinant human tissue kallikrien (rhKLK-1) protein to treat vascular and metabolic diseases.

Investors

Investors

$0.00 DMA
$0.00 TSX Venture Exchange
4/25/2014 4:00PM EDT
View Investor Relations ›